{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T01:33:31Z","timestamp":1793669611185,"version":"4.5.1"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000738","name":"Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Veterans Health Administration","id":[{"id":"https:\/\/ror.org\/05eq41471","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006379","name":"Office of Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006379","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clinical Sciences Research","award":["EPID-006-15S"],"award-info":[{"award-number":["EPID-006-15S"]}]},{"name":"Clinical Sciences Research","award":["R01EY026174"],"award-info":[{"award-number":["R01EY026174"]}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P30EY014801"],"award-info":[{"award-number":["P30EY014801"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.ajo.2018.11.007","type":"journal-article","created":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T05:21:42Z","timestamp":1542864102000},"page":"216-222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"special_numbering":"C","title":["Comparison of Topical 5-Fluorouracil and Interferon Alfa-2b as Primary Treatment Modalities for Ocular Surface Squamous Neoplasia"],"prefix":"10.1016","volume":"199","author":[{"given":"Nandini","family":"Venkateswaran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Mercado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3026-6155","authenticated-orcid":false,"given":"Anat","family":"Galor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol L.","family":"Karp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ajo.2018.11.007_bib1","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.ophtha.2004.02.013","article-title":"Clinical survey of 1643 melanocytic and nonmelanocytic conjunctival tumors","volume":"111","author":"Shields","year":"2004","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ajo.2018.11.007_bib2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0039-6257(05)80054-2","article-title":"Ocular surface squamous neoplasia","volume":"39","author":"Lee","year":"1995","journal-title":"Surv Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2018.11.007_bib3","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.ophtha.2013.11.017","article-title":"Surgical versus medical treatment of ocular surface squamous neoplasia: a comparison of recurrences and complications","volume":"121","author":"Nanji","year":"2014","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.ajo.2018.11.007_bib4","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1097\/ICO.0b013e31829e3c80","article-title":"Epidemiology of ocular surface squamous neoplasia in a Veterans Affairs population","volume":"32","author":"McClellan","year":"2013","journal-title":"Cornea"},{"issue":"3","key":"10.1016\/j.ajo.2018.11.007_bib5","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S0161-6420(01)00991-5","article-title":"Human papillomavirus 16 and 18 expression in conjunctival intraepithelial neoplasia","volume":"109","author":"Scott","year":"2002","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ajo.2018.11.007_bib6","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1001\/archopht.1997.01100150810025","article-title":"Surgical management of conjunctival tumors. The 1994 Lynn B. McMahan Lecture","volume":"115","author":"Shields","year":"1997","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2018.11.007_bib7","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/sj.eye.6700331","article-title":"Excision and cryosurgery in the treatment of conjunctival malignant epithelial tumours","volume":"17","author":"Peksayar","year":"2003","journal-title":"Eye (Lond)"},{"issue":"2","key":"10.1016\/j.ajo.2018.11.007_bib8","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ajo.2015.04.027","article-title":"Recurrence of ocular surface squamous neoplasia treated with excisional biopsy and cryotherapy","volume":"160","author":"Li","year":"2015","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2018.11.007_bib9","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0161-6420(86)33764-3","article-title":"Conjunctival and corneal intraepithelial and invasive neoplasia","volume":"93","author":"Erie","year":"1986","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2018.11.007_bib10","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0161-6420(97)30287-5","article-title":"Late recurrences and the necessity for long-term follow-up in corneal and conjunctival intraepithelial neoplasia","volume":"104","author":"Tabin","year":"1997","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2018.11.007_bib11","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/ICU.0b013e3283622a13","article-title":"Topical chemotherapy for ocular surface squamous neoplasia","volume":"24","author":"Nanji","year":"2013","journal-title":"Curr Opin Ophthalmol"},{"issue":"12","key":"10.1016\/j.ajo.2018.11.007_bib12","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1097\/ICO.0b013e3182a6ea6c","article-title":"Ocular surface squamous neoplasia: a survey of changes in the standard of care from 2003 to 2012","volume":"32","author":"Adler","year":"2013","journal-title":"Cornea"},{"issue":"3","key":"10.1016\/j.ajo.2018.11.007_bib13","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/01.ico.0000138834.42489.ba","article-title":"Ocular surface squamous neoplasia: a standard of care survey","volume":"24","author":"Stone","year":"2005","journal-title":"Cornea"},{"issue":"1","key":"10.1016\/j.ajo.2018.11.007_bib14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/17469899.2017.1263567","article-title":"Diagnosis and medical management of ocular surface squamous neoplasia","volume":"12","author":"Sayed-Ahmed","year":"2017","journal-title":"Expert Rev Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2018.11.007_bib15","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1001\/jama.1991.03470100067035","article-title":"The interferons. Mechanisms of action and clinical applications","volume":"266","author":"Baron","year":"1991","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ajo.2018.11.007_bib16","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2165\/00003495-200767020-00005","article-title":"The clinical applications of fluorouracil in ophthalmic practice","volume":"67","author":"Abraham","year":"2007","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.ajo.2018.11.007_bib17","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2165\/00003495-200666030-00005","article-title":"Mitomycin: clinical applications in ophthalmic practice","volume":"66","author":"Abraham","year":"2006","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.ajo.2018.11.007_bib18","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1136\/bjophthalmol-2016-309219","article-title":"Topical 1% 5-fluoruracil as a sole treatment of corneoconjunctival ocular surface squamous neoplasia: long-term study","volume":"101","author":"Parrozzani","year":"2017","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"10.1016\/j.ajo.2018.11.007_bib19","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/S0161-6420(97)30055-4","article-title":"Mitomycin C treatment for conjunctival-corneal intraepithelial neoplasia: a multicenter experience","volume":"104","author":"Frucht-Pery","year":"1997","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ajo.2018.11.007_bib20","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/APO.0000000000000104","article-title":"Topical interferon alpha-2b as a single therapy for primary ocular surface squamous neoplasia","volume":"4","author":"Kusumesh","year":"2015","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"issue":"3","key":"10.1016\/j.ajo.2018.11.007_bib21","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/ICO.0000000000001116","article-title":"Retrospective comparative study of topical interferon alpha2b versus mitomycin C for primary ocular surface squamous neoplasia","volume":"36","author":"Kusumesh","year":"2017","journal-title":"Cornea"},{"issue":"6","key":"10.1016\/j.ajo.2018.11.007_bib22","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","article-title":"The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM","volume":"17","author":"Edge","year":"2010","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.ajo.2018.11.007_bib23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF00166683","article-title":"Topical application of 5-fluorouracil in premalignant lesions of cornea, conjunctiva and eyelid","volume":"64","author":"de Keizer","year":"1986","journal-title":"Doc Ophthalmol"},{"issue":"12","key":"10.1016\/j.ajo.2018.11.007_bib24","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/S0161-6420(00)00389-4","article-title":"5-Fluorouracil for the treatment of intraepithelial neoplasia of the conjunctiva and cornea","volume":"107","author":"Yeatts","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2018.11.007_bib25","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2147\/OPTH.S9709","article-title":"5-Fluorouracil for the treatment of intraepithelial neoplasia and squamous cell carcinoma of the conjunctiva, and cornea","volume":"4","author":"Al-Barrag","year":"2010","journal-title":"Clin Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2018.11.007_bib26","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/bjo.2010.183244","article-title":"Topical 1% 5-fluorouracil in ocular surface squamous neoplasia: a long-term safety study","volume":"95","author":"Parrozzani","year":"2011","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajo.2018.11.007_bib27","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.ophtha.2016.02.034","article-title":"Topical 5-fluorouracil 1% as primary treatment for ocular surface squamous neoplasia","volume":"123","author":"Joag","year":"2016","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ajo.2018.11.007_bib28","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0002-9394(99)80252-9","article-title":"Interferon treatment for corneolimbal squamous dysplasia","volume":"125","author":"Hu","year":"1998","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2018.11.007_bib29","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0161-6420(99)90009-X","article-title":"Perilesional and topical interferon alfa-2b for conjunctival and corneal neoplasia","volume":"106","author":"Vann","year":"1999","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.ajo.2018.11.007_bib30","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1001\/archopht.1994.01090210029007","article-title":"Regression of limbal epithelial dysplasia with\u00a0topical interferon","volume":"112","author":"Maskin","year":"1994","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2018.11.007_bib31","doi-asserted-by":"crossref","first-page":"423","DOI":"10.4103\/2008-322X.150811","article-title":"Topical interferon alpha-2b for treatment of noninvasive ocular surface squamous neoplasia with 360 degrees limbal involvement","volume":"9","author":"Zarei-Ghanavati","year":"2014","journal-title":"J Ophthalmic Vis Res"},{"issue":"2","key":"10.1016\/j.ajo.2018.11.007_bib32","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/archophthalmol.2011.385","article-title":"Topical interferon alfa-2b for management of ocular surface squamous neoplasia in 23 cases: outcomes based on American Joint Committee on Cancer classification","volume":"130","author":"Shah","year":"2012","journal-title":"Arch Ophthalmol"},{"issue":"8","key":"10.1016\/j.ajo.2018.11.007_bib33","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.ophtha.2008.01.006","article-title":"Topical interferon or surgical excision for the management of primary ocular surface squamous neoplasia","volume":"115","author":"Sturges","year":"2008","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2018.11.007_bib34","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/ICO.0b013e3182523f61","article-title":"Interferon for ocular surface squamous neoplasia in 81 cases: outcomes based on the American Joint Committee on Cancer classification","volume":"32","author":"Shields","year":"2013","journal-title":"Cornea"},{"issue":"2","key":"10.1016\/j.ajo.2018.11.007_bib35","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ajo.2013.10.012","article-title":"Risk factors for ocular surface squamous neoplasia recurrence after treatment with topical mitomycin C and interferon alpha-2b","volume":"157","author":"Besley","year":"2014","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"10.1016\/j.ajo.2018.11.007_bib36","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.ophtha.2007.10.039","article-title":"Long-term follow-up of conjunctival and corneal intraepithelial neoplasia treated with topical interferon alfa-2b","volume":"115","author":"Schechter","year":"2008","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ajo.2018.11.007_bib37","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1136\/bjo.2008.153197","article-title":"Topical interferon alpha 2b eye-drops for treatment of ocular surface squamous neoplasia: a dose comparison study","volume":"94","author":"Galor","year":"2010","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2018.11.007_bib38","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/ICO.0000000000001153","article-title":"Immunosuppression as a possible risk factor for interferon nonresponse in ocular surface squamous neoplasia","volume":"36","author":"Ashkenazy","year":"2017","journal-title":"Cornea"},{"issue":"3","key":"10.1016\/j.ajo.2018.11.007_bib39","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/08820530500351694","article-title":"Topical medical therapies for ocular surface tumors","volume":"21","author":"Poothullil","year":"2006","journal-title":"Semin Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2018.11.007_bib40","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0002-9394(14)73072-7","article-title":"Mitomycin C therapy for corneal intraepithelial neoplasia","volume":"117","author":"Frucht-Pery","year":"1994","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajo.2018.11.007_bib41","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/00003226-200210000-00017","article-title":"Mitomycin C therapy for conjunctival-corneal intraepithelial neoplasia","volume":"21","author":"Papandroudis","year":"2002","journal-title":"Cornea"},{"issue":"5","key":"10.1016\/j.ajo.2018.11.007_bib42","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/00003226-199709000-00020","article-title":"Successful treatment of recurrent corneal intraepithelial neoplasia with topical mitomycin C","volume":"16","author":"Tseng","year":"1997","journal-title":"Cornea"},{"issue":"1","key":"10.1016\/j.ajo.2018.11.007_bib43","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/bjo.88.1.17","article-title":"Mitomycin C as an adjunct in the treatment of localised ocular surface squamous neoplasia","volume":"88","author":"Chen","year":"2004","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2018.11.007_bib44","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1136\/bjo.2009.168294","article-title":"Treatment of ocular surface squamous neoplasia with Mitomycin C","volume":"94","author":"Gupta","year":"2010","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2018.11.007_bib45","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0002-9394(14)70834-7","article-title":"Treatment of recurrent conjunctival epithelial neoplasia with topical mitomycin C","volume":"124","author":"Heigle","year":"1997","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2018.11.007_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00003226-200001000-00001","article-title":"Treatment of conjunctival intraepithelial neoplasia with topical drops of mitomycin C","volume":"19","author":"Rozenman","year":"2000","journal-title":"Cornea"},{"issue":"5","key":"10.1016\/j.ajo.2018.11.007_bib47","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0002-9394(02)01400-9","article-title":"Topical mitomycin C for extensive, recurrent conjunctival-corneal squamous cell carcinoma","volume":"133","author":"Shields","year":"2002","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2018.11.007_bib48","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0002-9394(14)70822-0","article-title":"Topical mitomycin C for the treatment of conjunctival and corneal epithelial dysplasia and neoplasia","volume":"124","author":"Wilson","year":"1997","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2018.11.007_bib49","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1136\/bjo.2009.176099","article-title":"Topical mitomycin C chemotherapy in the management of ocular surface neoplasia: a 10-year review of treatment outcomes and complications","volume":"94","author":"Russell","year":"2010","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2018.11.007_bib50","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jtos.2013.11.001","article-title":"Ultra high-resolution anterior segment optical coherence tomography in the diagnosis and management of ocular surface squamous neoplasia","volume":"12","author":"Thomas","year":"2014","journal-title":"Ocul Surf"},{"issue":"3","key":"10.1016\/j.ajo.2018.11.007_bib51","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ophtha.2011.08.028","article-title":"Ultra-high resolution optical coherence tomography for differentiation of ocular surface squamous neoplasia and pterygia","volume":"119","author":"Kieval","year":"2012","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2018.11.007_bib52","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jtos.2015.02.001","article-title":"High-resolution optical coherence tomography as an adjunctive tool in the diagnosis of corneal and conjunctival pathology","volume":"13","author":"Nanji","year":"2015","journal-title":"Ocul Surf"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939418306470?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939418306470?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T13:39:41Z","timestamp":1757597981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939418306470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":52,"alternative-id":["S0002939418306470"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2018.11.007","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of Topical 5-Fluorouracil and Interferon Alfa-2b as Primary Treatment Modalities for Ocular Surface Squamous Neoplasia","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2018.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}